Impel Pharmaceuticals Investor Relations Material
Latest events
Q1 2023
Impel Pharmaceuticals
Q3 2023
14 Nov, 2023
Q2 2023
18 Aug, 2023
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Impel Pharmaceuticals Inc
Access all reports
Impel Pharmaceuticals Inc is a biopharmaceutical company that develops intranasal drug delivery treatments for central nervous system disorders. The company’s delivery platform enables rapid and targeted administration of therapeutics for conditions such as migraines and Parkinson’s disease. It focuses on commercializing treatments through healthcare provider networks. Impel Pharmaceuticals Inc is headquartered in Seattle, Washington, and its shares are listed on the NASDAQ.
Latest articles
)
Eli Lilly: The Pharma Giant Behind Mounjaro and Zepbound
Eli Lilly's journey from insulin pioneer to global pharma giant, leading innovation in diabetes, obesity, and the future of metabolic health.
30 Jun 2025
)
500 Years of Craft, One Family Legacy: Beretta Holding's Global Expansion
How Beretta Holding managed to transform from a 16th-century gun barrel producer into a global industrial group while preserving 500 years of legacy.
27 Jun 2025
)
Shuntaro Furukawa: The Sixth President of Nintendo
Shuntaro Furukawa, Nintendo's sixth president, went from a childhood fan to leading the company through global expansion and the launch of Switch 2.
23 Jun 2025
Ticker symbol
IMPL
Country
🇺🇸 United States